| __timestamp | Gilead Sciences, Inc. | Taro Pharmaceutical Industries Ltd. |
|---|---|---|
| Wednesday, January 1, 2014 | 3788000000 | 179279000 |
| Thursday, January 1, 2015 | 4006000000 | 186359000 |
| Friday, January 1, 2016 | 4261000000 | 171785000 |
| Sunday, January 1, 2017 | 4371000000 | 208136000 |
| Monday, January 1, 2018 | 4853000000 | 198405000 |
| Tuesday, January 1, 2019 | 4675000000 | 224169000 |
| Wednesday, January 1, 2020 | 4572000000 | 245044000 |
| Friday, January 1, 2021 | 6601000000 | 252314000 |
| Saturday, January 1, 2022 | 5657000000 | 268225000 |
| Sunday, January 1, 2023 | 6498000000 | 304629000 |
| Monday, January 1, 2024 | 28675800000 | 324203000 |
In pursuit of knowledge
In the ever-evolving pharmaceutical industry, cost management is crucial for sustaining growth and innovation. This analysis compares the cost of revenue for Gilead Sciences, Inc. and Taro Pharmaceutical Industries Ltd. from 2014 to 2023. Gilead Sciences, a leader in antiviral drugs, consistently outpaces Taro, with costs peaking at approximately $6.6 billion in 2021, a 74% increase from 2014. Meanwhile, Taro, known for its dermatological products, shows a steady rise, reaching around $324 million in 2023, marking an 81% increase over the decade. Notably, Gilead's costs surged in 2021, possibly due to increased R&D investments. In contrast, Taro's gradual growth reflects its strategic market positioning. Missing data for Gilead in 2024 suggests potential reporting delays or strategic shifts. This comparison highlights the diverse strategies and challenges faced by pharmaceutical companies in managing their cost structures.
AbbVie Inc. vs Taro Pharmaceutical Industries Ltd.: Efficiency in Cost of Revenue Explored
Analyzing Cost of Revenue: Novartis AG and Taro Pharmaceutical Industries Ltd.
Cost of Revenue Trends: Bristol-Myers Squibb Company vs Gilead Sciences, Inc.
Analyzing Cost of Revenue: Gilead Sciences, Inc. and Ionis Pharmaceuticals, Inc.
Gilead Sciences, Inc. vs Amneal Pharmaceuticals, Inc.: Efficiency in Cost of Revenue Explored
Cost of Revenue Comparison: Gilead Sciences, Inc. vs Mesoblast Limited
Cost of Revenue: Key Insights for Viatris Inc. and Taro Pharmaceutical Industries Ltd.
Analyzing Cost of Revenue: Pharming Group N.V. and Taro Pharmaceutical Industries Ltd.
Comparing Cost of Revenue Efficiency: Grifols, S.A. vs Taro Pharmaceutical Industries Ltd.
Cost of Revenue Comparison: MorphoSys AG vs Taro Pharmaceutical Industries Ltd.
Geron Corporation vs Taro Pharmaceutical Industries Ltd.: Efficiency in Cost of Revenue Explored
Cost of Revenue Comparison: Taro Pharmaceutical Industries Ltd. vs Xencor, Inc.